VEGF 靶向治疗及其生物标志物在晚期结直肠癌中的研究进展
作者: |
1林泽鑫,
1劳学军
1 暨南大学附属第一医院 普通外科,广东 广州 510000 |
通讯: |
劳学军
Email: foxlxj2k@126.com |
DOI: | 10.3978/.10.3978/j.issn.1005-6947.2015.04.021 |
摘要
结直肠癌(CRC)是世界范围内癌症发病与致死的主要因素,近几年分子靶向治疗的临床应用为晚期 结直肠癌治疗带来了曙光。贝伐珠单抗被批准应用于一线和二线晚期结直肠癌的治疗,促使了以血管 内皮生长因子(VEGF)为作用靶点的靶向治疗药物不断涌现,并在临床试验中取得显著疗效。笔者就 VEGF 靶向治疗及其生物标志物在晚期结直肠癌中的研究进展进行综述。
关键词:
结直肠肿瘤
肿瘤转移
血管内皮生长因子类
生物学标记
综述文献
VEGF-targeted therapy for metastatic colorectal cancer and related biomarkers: recent advances
CorrespondingAuthor:LAO Xuejun Email: foxlxj2k@126.com
Abstract
Colorectal cancer (CRC) is a major contributor to cancer morbidity and mortality worldwide. Recently, the clinical application of molecular targeting therapy brings hope for treatment of metastatic CRC (mCRC). Following the approval of bevacizumab as first- and second-line treatment of mCRC, the therapeutic agents targeting vascular endothelial growth factor (VEGF) have been emerging constantly, and also shown significant efficacy in clinical trials. In this paper, the authors address the progress in VEGF-targeted therapy and the related biomarkers for mCRC.
Keywords: